2026’s Tech Stack: Multimodal AI, Solid‑State Batteries, and the New Era of Gene Editing

Tech in 2026 is less about spectacle and more about infrastructure. The most meaningful shifts are happening in the underlying systems: AI models that can see and hear, batteries that can charge in minutes instead of hours, and medical pipelines that can deliver therapies to a single patient. These are not just product launches; they are new capabilities that can change how industries work. Below is a deep dive into three non‑political trends that are genuinely shaping the year: AI models and providers, electric vehicles and autonomy, and biotech’s move toward individualized gene editing.

1) AI models are getting longer memories and broader senses

In the last year, the AI conversation has moved from “Which model is best at writing?” to “Which model can understand everything we throw at it?” Providers are converging on two ideas: multimodality (text + images + audio + video in one model) and longer context windows (the ability to keep massive documents or codebases in memory). Together, these are unlocking new product categories — assistants that can actually operate inside work, not just answer questions.

OpenAI’s GPT‑4o and the mainstreaming of multimodal models

OpenAI’s GPT‑4o (the “o” stands for omni) is positioned as a flagship model that accepts multiple media types and can respond in more natural, real‑time ways. The most important change here is not a single benchmark; it’s the fact that text, audio and vision are handled in one model rather than stitched together with separate tools. IBM’s overview of GPT‑4o highlights its multimodal capability and emphasis on natural audio interactions, plus a smaller sibling model (GPT‑4o mini) designed for speed and lower cost (IBM overview). This “one model, many modalities” approach is shaping how teams design AI experiences — from voice interfaces to real‑time translation to multimodal copilots for support desks.

There’s also a broader platform effect: once a model can see, listen and speak, the bottleneck becomes workflow integration rather than capability. This is why providers are investing in tool calling, guardrails, and safe multimodal outputs. For product teams, the real takeaway is that AI is becoming less like a chatbot and more like a universal interpreter between data types. That is the kind of general capability that eventually gets baked into operating systems, enterprise software and consumer devices.

Google’s Gemini 1.5 Pro and the “long context” era

Long context is the other big pivot. Google’s Gemini 1.5 Pro rollout to Gemini Advanced is a clear example: a 1 million token context window that can absorb huge documents, long conversations or large codebases. Google’s product blog notes that this enables analysis of up to 1,500 pages and deeper data‑analysis workflows, plus file uploads and integration with Google apps (Google Gemini update). The important shift is that context isn’t a luxury anymore — it’s the foundation for real productivity use cases.

When a model can handle large context, it becomes viable for tasks like compliance review, enterprise search, product documentation mapping and long‑form research. Instead of “summarize this,” you can ask for structured comparisons across hundreds of pages, build decision trees, or transform a whole codebase with consistent rules. This changes procurement conversations: for many enterprises, “context length” is now as meaningful as raw model quality. It’s also driving a new ecosystem of tools that chunk, index and retrieve data — not because models can’t see large inputs, but because teams want finer‑grained control over what is included and how it’s reasoned about.

Anthropic’s Claude 3 family and the tiered‑model strategy

Anthropic’s Claude 3 announcement shows another trend: tiered model families for different workloads. The Claude 3 lineup — Haiku, Sonnet and Opus — is designed to let teams choose speed, cost and capability based on task complexity. Their announcement emphasizes improvements in reasoning, multilingual fluency and vision, along with lower refusal rates and faster responses across the family (Anthropic Claude 3 family). This is now a common provider strategy: rather than one “best model,” companies ship a portfolio so developers can mix and match inside products.

That portfolio approach is important because real applications often need multiple tiers: a fast model for low‑risk tasks, a mid‑tier model for structured analysis, and a premium model for complex reasoning. It’s not unlike how cloud teams use different compute instances. For AI, the implication is that cost optimization and orchestration are becoming core product features. In other words, the “model router” is now part of the application, and providers are encouraging it by offering differentiated models.

What’s actually trending in AI this year?

Put together, the trend is clear: the AI stack is widening. It’s no longer just about text. It’s about multimodal inputs, long context, model portfolios, and workflow integration. These capabilities are pushing AI into more serious settings: audio‑first customer support, document‑heavy legal work, multimedia tutoring, and codebase‑scale refactoring. The more the model can absorb, the less engineering overhead it takes to make AI feel reliable and “aware.” And that means more products can launch without months of bespoke prompt engineering.

From a business standpoint, AI spend is shifting from experimentation to operations. Teams are now asking: How do we make this cheaper, more reliable, and safer? That’s why cost‑efficient models like GPT‑4o mini or fast models like Claude 3 Haiku matter. The winners in this cycle are likely to be providers that offer a tight spectrum: powerful enough for complex reasoning but efficient enough for everyday use.

2) EVs are moving beyond range anxiety toward systems thinking

Electric vehicles are no longer just about how far you can drive. The new conversation is about the entire ecosystem: battery chemistry, charging speed, cost curves, recycling and grid integration. For consumers, the shift feels like faster charging and better reliability. For industry, it’s about the supply chain and total cost of ownership.

Battery trends: ultra‑fast charging, recycling, and high‑voltage systems

A recent CALSTART overview of EV battery trends lays out the major themes that are moving into 2026: ultra‑fast charging, second‑life battery use, and higher‑voltage architectures (such as 800‑volt systems) that reduce weight and increase efficiency (CALSTART battery trends). This trend list reads like an industry playbook: make charging fast enough to feel like refueling, make batteries last longer via reuse, and reduce costs by optimizing materials and system design.

What’s interesting is that these changes are interconnected. High‑voltage systems make ultra‑fast charging more practical. Battery recycling lowers cost pressure and improves sustainability narratives for regulators and consumers. And second‑life applications (like grid storage) can improve the economics of EV ownership, which in turn supports adoption. The point is that the EV revolution is becoming a systems upgrade, not just a vehicle upgrade.

Solid‑state batteries are moving from hype to pilot testing

Solid‑state batteries have been the “next big thing” for years. The difference now is the emergence of real‑world testing. According to Electrek, Volkswagen partner Gotion High Tech has begun testing its all‑solid‑state batteries in vehicles, with reported energy density around 350 Wh/kg and a target range of 1,000 km in the Chinese test cycle (Electrek: Gotion testing). The article also notes pilot‑scale production progress and additional chemistries under development.

It’s important to stay realistic: pilot testing is not mass production, and range claims are often optimistic. But the practical milestone here is vehicle integration. Solid‑state is finally leaving lab cells and entering test fleets, which is a key step toward manufacturing readiness. If 2025 was about proving the chemistry, 2026 is about learning what breaks when the battery is placed in a real vehicle under real conditions. Those lessons — thermal behavior, manufacturing yield, safety cases — are what ultimately determine if the tech graduates into consumer cars.

Autonomy is getting less flashy and more useful

One of the more interesting auto stories this year is a partial retreat from Level 3 autonomy. Carscoops reports that BMW is dropping its Level 3 system in favor of a more affordable Level 2 system derived from the Neue Klasse platform, citing cost and regulatory complexity (Carscoops: BMW L3 to L2). This aligns with a broader industry shift: automakers are focusing on robust Level 2+ systems that are cheaper, easier to validate and more consistent across markets.

This doesn’t mean autonomy is “dead.” It means real‑world adoption is converging on features that drivers actually use: hands‑free highway cruising, automated lane changes, and assisted navigation. These are the features that create daily value and can be shipped broadly. The long‑term path to Level 4 or Level 5 autonomy still exists, but the near‑term business case is in practical driver assistance that works across geographies and regulations.

What’s actually trending in EV tech this year?

The trend is maturation. We’re seeing steady improvements across the entire EV stack: better charging speeds, smarter battery reuse, higher‑voltage architectures and steady progress in new chemistries. The automakers that win in this cycle won’t be the ones with the most hype — they’ll be the ones who can ship reliable vehicles at scale, with charging experiences that feel “normal.” As solid‑state batteries move into fleet tests, the industry will learn whether they can deliver the safety and manufacturing gains they promise. That knowledge will shape late‑decade EV strategies.

3) Biotech is entering the era of individualized therapy

The biotech story of 2026 is not just about better tools — it’s about a new pathway for how therapies are approved and scaled. The ability to design a gene‑editing treatment for a single patient used to be a scientific miracle. Now regulators are constructing frameworks that could make it repeatable. This is the point where innovation moves from the lab into the healthcare system.

The FDA’s framework for individualized therapies

In February 2026, the U.S. Department of Health and Human Services announced that the FDA had issued draft guidance for individualized therapies targeting ultra‑rare diseases. The framework, focused on genome editing and RNA‑based therapies, aims to allow approvals even when randomized clinical trials aren’t feasible due to tiny patient populations (HHS press release). The guidance emphasizes “substantial evidence” of effectiveness and safety, but recognizes that evidence may need to be built from small, well‑controlled investigations rather than large trials.

This is a big deal: regulatory uncertainty has historically been one of the largest barriers to personalized gene therapies. By creating a pathway, regulators are essentially acknowledging that the “N‑of‑1” model could become a legitimate therapeutic strategy. This doesn’t mean rapid approvals without oversight; it means a consistent framework for evaluating individualized treatments when large trials are impossible. That’s a signal to biotech companies and academic labs that investments in bespoke therapies might now have a clearer route to patients.

Why this matters for gene editing and CRISPR

CRISPR is no longer a theoretical tool. The Innovative Genomics Institute’s 2025 update on CRISPR clinical trials notes real‑world progress, including the first approved CRISPR‑based therapy (Casgevy) and the growing number of clinical trial sites in multiple regions (IGI CRISPR clinical trials update). That report also references the first personalized CRISPR treatment for a patient, a case that demonstrated the feasibility of rapidly designing a bespoke therapy for an ultra‑rare condition. The message is clear: the technology is transitioning from proof‑of‑concept to clinical infrastructure.

Biopharma Dive’s coverage of the FDA guidance provides further context: the agency is outlining how individualized therapies should demonstrate a plausible mechanism, use natural history data, and show meaningful clinical outcomes or biomarkers (BioPharma Dive analysis). This is not a shortcut; it’s a structured path tailored to cases where standard randomized trials are unrealistic. It’s a recognition that rare disease families cannot wait for the traditional pipeline to catch up.

What’s actually trending in biotech this year?

The trend is regulatory clarity plus technical acceleration. Gene editing tools are improving — with greater precision and fewer off‑target effects — but the bigger story is that the system is now preparing to support individualized therapies at scale. This doesn’t mean every rare disease will suddenly have a cure, but it does mean that the science can be translated more quickly when a target is well understood. The next stage will be operational: manufacturing workflows, quality control, and reimbursement models that make personalized therapies viable beyond a handful of cases.

4) The common thread: scale and integration

Across AI, EVs and biotech, the same pattern appears. Capabilities are moving from novelty to scale. AI models are expanding their input space; EV systems are becoming more integrated with energy infrastructure; gene editing is gaining regulatory frameworks that allow more repeatable development. In each domain, the next bottleneck is not just technical, but operational: How do you ship this safely? How do you keep it affordable? How do you integrate it into everyday workflows?

That’s why 2026 feels like a year of maturity. It’s not about a single breakthrough but about building reliable systems around breakthroughs. The most important innovations are the ones that make new capabilities practical — from the model routers that choose the right AI tier for a task, to the manufacturing systems that can create bespoke gene therapies, to the charging networks that turn high‑voltage batteries into real consumer convenience.

5) What to watch next

Here are a few concrete signals worth tracking over the next 6–12 months:

• AI: Continued growth in long‑context models and wider adoption of multimodal assistants in enterprise apps, not just consumer demos.
• EVs: Pilot‑scale solid‑state fleets and the rollout of higher‑voltage architectures in mainstream models.
• Autonomy: More focus on reliable Level 2+ features, fewer headline‑grabbing Level 3 promises.
• Biotech: Implementation of FDA’s individualized therapy framework and early examples of new approvals based on the “plausible mechanism” pathway.

These are not speculative moonshots. They’re the boring, structural upgrades that make the tech world feel different in practice. That’s why they matter more than the loudest headlines.

Conclusion: The year of quiet, compounding progress

If 2024 and 2025 were about discovery and hype, 2026 is about hardening the stack. AI providers are shipping models that can handle the messy inputs of real life. EV makers are improving the entire battery ecosystem and shifting autonomy toward practical features. Biotech is turning gene editing into a repeatable, regulated path for individualized care. These changes don’t always look dramatic — but they compound. And by the time the next wave of products arrives, the groundwork laid in 2026 will be what made them possible.

That’s the story to watch: not just the breakthrough, but the system that turns a breakthrough into something people can actually use.